UNSPSC 51284508: Lincomycin hydrochloride anhydrous

This classification denotes a lincosamide antibiotic with the molecular formula C18H34N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCW8Y9936L, chemically known as d-erythro-.alpha.-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, monohydrochloride, (2s-trans)-, but more generally known as lincomycin hydrochloride anhydrous, which bears US NIH Compound Identifier 64710.

UNSPSC 51284508 Lincomycin hydrochloride anhydrous is a Commodity code that nominally addresses a specific antibiotic pharmaceutical, yet recent state and local opportunities posted under this code show minimal activity directly aligned with lincomycin procurement. The source records instead capture broader pharmaceutical and medical supply solicitations that diverge significantly from the code's narrow scope, including naloxone systems, generic multi-source pharmaceuticals, and emergency medical supplies. This mismatch suggests the code may be underutilized or tagged inconsistently in state and local procurement systems, and the actual buying activity under this Commodity does not track with recent open market opportunities.

The geographic spread of available records spans Florida, Texas, and Minnesota, with issuing bodies including county health departments (Seminole County), state health agencies (Texas HHS Commission), municipalities (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the City of Tampa's IFB for medical and first aid supplies serving the Fire Department Rescue Division, estimated at $700,000, with a March 13, 2026 deadline and a five-percent Small Local Business Enterprise bid discount not to exceed $10,000; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and over-the-counter products due March 26, 2026. No solicitations specifically targeting lincomycin hydrochloride anhydrous procurement appear in the recent opportunities block, indicating minimal current market demand under this Commodity code.